Melissa Jessica Huynh

Melissa Jessica Huynh

Auto-generated profile, based on publicly available information

Melissa Jessica Huynh

Department of Medical Imaging, and Division of Urology, Department of Surgery, Western University, London, Ontario, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in American Society of Clinical Oncology Educational Book
Verified
Journal Article
Closed access
RLRoss S. Liao
Ross S. Liao
HRHui Ting Ruan
Hui Ting Ruan
AJAlbert Jang
Albert Jang
MHMelissa Huynh
Melissa Huynh
RRRosa Nadal Rios
Rosa Nadal Rios
PBPedro Barata
Pedro Barata
Small-cell carcinomas (SCCs) of the genitourinary (GU) tract are rare malignancies with high metastatic potential. The most common primary sites are the bladder and prostate, but case reports of primary SCC of the kidney, ureter, and urethra also exist. The majority of patients present with gross hematuria, irritative or obstructive urinary symptoms, and symptoms of locoregionally advanced or metastatic disease at initial presentation. SCC of the bladder presents with nodal or metastatic involvement in the majority of cases and requires the use of platinum-based chemotherapy in combination with surgery and/or radiation. SCC of the prostate is most commonly seen in the metastatic castrate-resistant setting, and aggressive variant disease presents with a greater propensity for visceral metastases, osteolytic lesions, and relatively low serum prostate-specific antigen for volume of disease burden. Multiple retrospective and prospective randomized studies support the use of a multimodal approach combining platinum-based systemic therapy regimens with radiation and/or surgery for localized disease. This evidence-based strategy is reflected in multiple consensus guidelines. Emerging data suggest that small-cell bladder and prostate cancers transdifferentiate from a common progenitor of conventional urothelial bladder carcinoma and prostatic acinar adenocarcinoma, respectively. Areas of active basic research include efforts to identify the key genetic and epigenetic drivers involved in the emergence of small cell cancers to exploit them for novel therapies. Here, we review these efforts, discuss diagnosis and currently supported management strategies, and summarize ongoing clinical trials evaluating novel therapies to treat this rare, aggressive GU cancer.

15 September 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
IHInbar A Habaz
Inbar A Habaz
XOXuejin Ou
Xuejin Ou
NWNicole I Wang
Nicole I Wang
ASAngela Schincaglia
Angela Schincaglia
VSValeryia Shydlouskaya
Valeryia Shydlouskaya
SHS.M. Mansour Haeryfar
S.M. Mansour Haeryfar
Background: Mucosa-associated invariant T (MAIT) cells represent a unique population of innate-like T lymphocytes capable of detecting non-peptide antigens in the context of monomorphic antigen-presenting molecules. Due to their abundance in barrier tissues, reactivity to local inflammatory cues, and cytotoxic and regulatory functions, MAIT cells are poised to shape the dynamics of various tumor microenvironments. Growing evidence suggests that MAIT cells can exert protumor and/or antitumor effects in cancers arising from or metastasizing to mucosal tissues. However, MAIT cell roles in bladder cancer (BCa) remains unclear. Methods: To begin to identify MAIT cells in BCa, we stained bladder tumor biopsies for T cell receptor (TCR) Vα7.2 + cells. We then refined a human MAIT cell signature, which enabled us to interrogate a bulk RNA sequencing dataset and conduct correlation analyses linking intratumoral MAIT cell abundance and mortality from BCa. To extend our work to an in vivo setting, we employed a clinically relevant mouse model in which Mr1 +/+ B6-MAIT CAST (MAIT-sufficient) and Mr1 −/− B6-MAIT CAST (MAIT-deficient) mice were exposed to N-butyl-N-(4-hydroxybutyl)nitrosamine, a chemical carcinogen associated with tobacco smoke. In additional experiments, MAIT cells were functionally removed through acetyl-6-formylpterin (Ac-6-FP) administration. Effector and regulatory cell types were phenotyped by flow cytometry, and BCa tumor burden and progression were assessed by MRI and/or H&E and Ki67 staining. Results: TCR Vα7.2 + cells were readily detectable in several BCa biopsies, and our bioinformatic analyses correlated heavier MAIT cell presence in BCa tumors with poorer overall survival. Similarly, we found higher tumor burdens in Mr1 +/+ B6-MAIT CAST mice than in Mr1 −/− or Ac-6-FP-treated animals. Bladder MAIT cells from tumor-bearing mice exhibited phenotypic MAIT17 bias based on transcription factors they harbored along with increased interleukin-17A and tumor necrosis factor-α production capacities upon stimulation. Finally, FoxP3 + regulatory T (T reg ) cell frequencies were elevated in Mr1 +/+ mouse bladder tumors, likely contributing to an immunosuppressive tumor microenvironment, a finding that could be recapitulated in our transcriptomic studies on human BCa. Conclusions: MAIT cells are abundant in BCa tumor microenvironments where they potentiate T reg cell accumulation and play protumor roles.

3 June 2025 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
Derek W Cool, MD, PhD, FSIR, FRCPCDerek W Cool, MD, PhD, FSIR, FRCPC
Derek W Cool, MD, PhD, FSIR, FRCPC
LCLeandro Cardarelli Cardarelli-Leite
Leandro Cardarelli Cardarelli-Leite
DLDavid Laidley
David Laidley
JRJonathan Romsa
Jonathan Romsa
AMAmol Mujoomdar
Amol Mujoomdar
MHMelissa Huynh
Melissa Huynh

20 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LBLaura Burgess
Laura Burgess
CAChristopher M. Aldrighetti
Christopher M. Aldrighetti
AGAnushka Ghosh
Anushka Ghosh
ANAndrzej Niemierko
Andrzej Niemierko
FCFumiko Chino
Fumiko Chino
SKSophia C. Kamran
Sophia C. Kamran
51 Background: The U. S. Preventative Services Task Force (USPSTF) recommendation regarding prostate-specific antigen (PSA) transitioned to a grade D recommendation against PSA screening for adult males in 2012. The impact of this recommendation against PSA screening on prostate cancer-specific mortality (PCSM) in contemporary cohorts is unknown. Our study evaluated PCSM between 1999-2019, comparing mortality rates before and after this change to screening guidelines. Methods: Age-adjusted PCSM rates per 100,000 men were obtained from the National Center for Health Statistics from 1999 – 2019. Trends in PCSM rates from 1999 – 2012 and 2014 – 2019 were estimated using linear regression with year and binary indicator of pre-2013/post-2013 status as interaction terms. Age-adjusted rates of PCSM were calculated for men ≥50 years and by race, ethnicity, urbanization and census region. Similarly, age-adjusted rates of overall cancer mortality (exclusive of PCSM) were calculated. Behavioral Risk Factor Surveillance System was used to establish trends in PSA screening from 2001 – 2018. North American Association of Central Cancer Registries was used to determine age-adjusted incidence of localized and metastatic PC at the time of diagnosis from 1999 – 2017. Results: The age-adjusted PCSM rate in the U.S. decreased linearly at a rate of (-)0.28 per 100,000/year from 1999 – 2012 and subsequently stalled at a rate of no change from 2014 – 2019 (p < 0.001). This effect was particularly striking for men aged 60 – 69, men > 80 years, and Black men. Men aged 60 – 64 had a decreasing rate of (-)0.009 per 100,000/year prior to 2013, followed by a rise of (+)0.001 per 100,000/year (p < 0.001). Among Black men, PCSM rate was decreasing linearly at (-)0.700/100,000/year from 1999-2012 and flattened at a rate of (-)0.091/100,000/year from 2014-2019 (p < 0.001). These changes were seen across races, urbanization and census regions (p < 0.001) and were accompanied by decreases in PSA screening (p = 0.02) together with increases in diagnosis of metastatic disease. These trends were inconsistent with mortality trends observed across all malignancies. Conclusions: Using comprehensive data on PCSM through 2019, this study illustrates decreasing PCSM over time which flattened or increased following the 2012 change in USPSTF guideline, along with a decrease in PSA screening. The change in PCSM was seen in all ages, races, ethnicities, urbanization and census regions, but particularly in men from 60 – 69 and > 80 years old, and Black men. These changes were accompanied by increased diagnosis of metastatic PC and are discordant from trends across other malignancies. These findings suggest that the change in PSA screening guideline may have contributed to the stagnancy of PCSM rates in recent years. The updated 2018 USPSTF guideline supporting shared-decision making may reverse these trends over time.

9 April 2026 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
CDCameron Dawson
Cameron Dawson
LBLakhdeep Brar
Lakhdeep Brar
CRCristian Rey
Cristian Rey
MHMelissa J. Huynh
Melissa J. Huynh
Derek W Cool, MD, PhD, FSIR, FRCPCDerek W Cool, MD, PhD, FSIR, FRCPC
Derek W Cool, MD, PhD, FSIR, FRCPC
To characterize the clinical and tube maintenance outcomes for patients with ileal conduits who require chronic urinary drainage with retrograde transileal ureteric stents (RUSs). A retrospective study from January 2010 to December 2021 reviewed 30 patients with chronic RUS drainage (1,148 exchange procedures), evaluating the adverse events (AEs), maintenance burden, and change in renal function. RUS results were compared with 71 conventional patients managed with chronic percutaneous nephrostomy (PCN) (1,068 exchanges). Change in renal function was not significantly different between RUS and PCN patients at 1 year (glomerular filtration rate [GFR], -10 mL/min/1.73 m2 vs -5 mL/min/1.73 m2; P = .16) and 2-3 years (GFR, -16 mL/min/1.73 m2 vs -7 mL/min/1.73 m2; P = .38) after insertion. RUS had lower rates of nonroutine interventions (5.9% vs 20.1%, P < .001) due to fewer tube dislodgement events; however, RUS required shorter routine maintenance intervals (P = .019) with median routine exchanges booked every 8.5 weeks (interquartile range [IQR], 6.3-10.9 weeks) at 3 years compared with 12.9 weeks (IQR, 9.5-13.1 weeks) for PCN patients. At 1 year after insertion, 30% of RUS patients required routine exchange intervals ≤6 weeks (3% for PCN patients). Unlike PCN, every year, more RUS patients required shorter routine maintenance intervals, typically due to tube encrustation, with 81% of patients requiring exchange intervals < 10 weeks at 4 years after insertion compared with 47% at 1 year. RUS patients experienced higher rates of moderate to severe AEs (30% vs 4.2%, P < .001), mostly due to tube dislodgements requiring a new PCN insertion under sedation to reestablish the RUS. Chronic RUS is effective for urinary diversion but requires significantly shorter intervals between routine tube maintenance than conventional PCN.